Registry, Oct 31, 2029
Dosing n/r
alkylating chemotherapy · Alliance
Disease Pipeline Tools IDH-mutant glioma
IDH-mutant glioma
Programs, trials, and reported response and survival for IDH-mutant glioma.
IDH-mutant glioma
Programs by company or class, across phase, filing, approval, and a stop.
A black mark is a readout. A yellow mark is another company date. A circle is an approval or an FDA action date the source names. A hollow mark is a registry primary completion date.
Phase 1 included.
Clear filters15 of 15 programs on this matrix
| Phase 1 | Phase 2 | Phase 3 | Filed | Approved | Discontinued | |
|---|---|---|---|---|---|---|
| Alliance1 program | Registry, Oct 31, 2029 Dosing n/r alkylating chemotherapy · Alliance | |||||
| ECOG-ACRIN1 program | Registry, Dec 31, 2026 Dosing n/r alkylating chemotherapy · ECOG-ACRIN | |||||
| GEINO1 program | Registry, Sep 2028 Dosing n/r ATR inhibitor (ATRX-altered) · GEINO | |||||
| German Cancer Research Center1 program | Registry, Dec 31, 2032 subcutaneous peptide vaccine · German Cancer Research Center | |||||
| Hospices Civils de Lyon (OLAGLI)1 program | Registry, Jan 2027 twice daily, oral PARP inhibitor · Hospices Civils de Lyon (OLAGLI) | |||||
| Hutchmed1 program | Registry, Dec 2026 once daily, oral mutant IDH1/IDH2 inhibitor · Hutchmed | |||||
| Massachusetts General Hospital2 programs | Phase 1 Dosing n/r PARP inhibitor · Massachusetts General Hospital Registry, Jan 2027 Dosing n/r DNMT inhibitor · Massachusetts General Hospital | |||||
| National Cancer Institute1 program | Phase 2 Dosing n/r PD-1 antibody · National Cancer Institute | |||||
| Nuvation Bio1 program | Registry, Dec 2028 twice daily, oral mutant IDH1 inhibitor · Nuvation Bio | |||||
| Rigel1 program | Registry, Jun 2029 twice daily, oral mutant IDH1 inhibitor · Rigel | |||||
| Servier2 programs | Phase 1 once daily, oral mutant IDH1 inhibitor · Servier | SNO 2026: INDIGO 41.6-month, seizure/QoL, real-world grade 2 and 3, Nov 12, 2026 once daily, oral mutant IDH1/IDH2 inhibitor · Servier | ||||
| University of California, San Francisco1 program | Phase 1 Dosing n/r PARP inhibitor · University of California, San Francisco | |||||
| University of Pennsylvania (Stephen Bagley)1 program | Registry, Jun 2027 Dosing n/r retinoid plus PD-1 antibody · University of Pennsylvania (Stephen Bagley) |